2,826 results on '"Maehara, Y."'
Search Results
2. The SCRIT electron scattering facility at RIKEN RI Beam Factory
3. Ion-trapping properties of SCRIT: Time evolutions of 138Ba charge state distributions
4. Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5)
5. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
6. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
7. First Observation of Electron Scattering from Online-Produced Radioactive Target
8. Immunotherapy: PHASE 1/2 MULTICENTER CLINICAL TRIAL OF TOLERANCE INDUCTION IN LIVING DONOR LIVER TRANSPLANTATION VIA INDUCED T CELLS WITH SUPPRESSING FUNCTIONS
9. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
10. Correlation Between Portal Vein Anatomy and Bile Duct Variation in 407 Living Liver Donors
11. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))
12. 323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial
13. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome
14. Revisiting the Safety of Living Liver Donors by Reassessing 441 Donor Hepatectomies: Is a Larger Hepatectomy Complication-Prone?
15. Hepatobiliary and Pancreatic: Pregnancy induced hepatic veno‐occlusive disease requiring liver transplantation
16. Indication of living donor liver transplantation for septuagenarians from double equipoise theory
17. Impact of systemic inflammatory response syndrome and surgical Apgar score on post‐operative acute kidney injury
18. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study
19. Primary Graft Dysfunction After Living Donor Liver Transplantation Is Characterized by Delayed Functional Hyperbilirubinemia
20. Left Lobe Living Donor Liver Transplantation in Adults
21. Impact of Human T Cell Leukemia Virus Type 1 in Living Donor Liver Transplantation
22. Deceleration of Regenerative Response Improves the Outcome of Rat with Massive Hepatectomy
23. Functional assessment of the liver with gadolinium–ethoxybenzyl-diethylenetriamine penta-acetate-enhanced MRI in living-donor liver transplantation
24. Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation
25. The Benefits of Interferon Treatment in Patients Without Sustained Viral Response After Living Donor Liver Transplantation for Hepatitis C
26. Rapid Normalization of Portopulmonary Hypertension After Living Donor Liver Transplantation
27. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension: Efecto de la esplenectomía laparoscópica en la hemodinámica portal de pacientes con cirrosis hepática e hipertensión portal
28. Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells
29. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma
30. Donor Age in Living Donor Liver Transplantation
31. Estimation of Standard Liver Volume for Japanese Adults
32. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant
33. Decreased immunoglobulin G levels after living-donor liver transplantation is a risk factor for bacterial infection and sepsis
34. Oxidative DNA damage in human esophageal cancer: clinicopathological analysis of 8-hydroxydeoxyguanosine and its repair enzyme
35. Determining fluid saturations in a low resistivity, heterogeneous siliciclastic oil reservoir, offshore Vietnam
36. Rock Physics Modelling of Gas Dissolved in Water Sandstone, Nakajo Field, Japan
37. Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C
38. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma
39. Rho-kinase as a novel gene therapeutic target in treatment of cold ischemia/reperfusion-induced acute lethal liver injury: effect on hepatocellular NADPH oxidase system
40. A case of an inflammatory myofibroblastic tumor in the lung which expressed TPM3–ALK gene fusion
41. Laparoscopic cholecystectomy using a newly developed laparoscope manipulator for 10 patients with cholelithiasis
42. Successful ABO Incompatible Living Donor Liver Transplantation in a Patient With High Isoagglutinin Titer Using High-Dose Intravenous Immunoglobulin
43. Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma
44. Is graft size a major risk factor in living-donor adult liver transplantation?
45. Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma
46. Esophageal replacement by colon interposition with microvascular surgery for patients with thoracic esophageal cancer: the utility of superdrainage
47. Surface structures of K on Mo(1 1 0) surface investigated by RHEED
48. Preparation of CMC Acid Gel and its Applications
49. PHASE II STUDY ALTERNATING MFOLFOX 6 AND FOLFIRI (FIREFOX) PLUS BEVACIZUMAB (BEV) REGIMEN IN FIRST-LINE TREATMENT OF ADVANCED COLORECTAL CANCER IN JAPANESE PATIENTS (KSCC 0801)
50. PHASE II STUDY OF COMBINATION THERAPY WITH S-1 AND CETUXIMAB IN PATIENTS WITH KRAS WILD-TYPE UNRESECTABLE COLORECTAL CANCER, WHO HAD PREVIOUSLY RECEIVED IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES (KSCC0901)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.